Outcomes Among Hospitalized Patients With COVID-19 and AKI: Role of SARS-CoV-2 Vaccine

ABSTRACT

Background: COVID-19 and Acute kidney injury (AKI) are associated with increased mortality and worse kidney outcomes. Although vaccines against SARS-CoV-2 have decreased the rate COVID-19 morbimortality, the role of immune protection against SARS-CoV-2 in the setting of AKI has not been fully yielded Methods: Retrospective case-control study that included clinical and biochemical data of 412 (78 vaccinated and 334 non-vaccinated) patients with severe COVID-19. Cox regression analyses were used to evaluate the effect of the vaccine in mortality and AKI outcomes Results: The mean age of the patients was 55+/-15 years, 64% were women, the mean body mass index was 28+/-5 kg/m2, and median in-hospital stay was 10(6-16) days. The rate of mortality and AKI 3 was 29% vs 10% and 27% vs 13%, for unvaccinated and vaccinated patients, respectively. Cox proportional hazard ratios for survival and prevention of AKI are shown in table 1 Conclusion(s) The SARS-CoV-2 vaccine was independently associated with lower mortality and AKI progression in patients with severe COVID-19.